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inhibition of Serine protease 
Activity protects Against High fat 
Diet-Induced Inflammation and 
insulin Resistance
chin-Sung Kuo1, Jia-Shiong chen2, Liang-Yu Lin  3, Geert W. Schmid-Schönbein4, Shu chien5, 
po-Hsun Huang6*, Jaw-Wen chen  7* & Shing-Jong Lin8*
Recent evidence suggests that enhanced protease-mediated inflammation may promote insulin 
resistance and result in diabetes. this study tested the hypothesis that serine protease plays a pivotal 
role in type 2 diabetes, and inhibition of serine protease activity prevents hyperglycemia in diabetic 
animals by modulating insulin signaling pathway. We conducted a single-center, cross-sectional study 
with 30 healthy controls and 57 patients with type 2 diabetes to compare plasma protease activities 
and inflammation marker between groups. Correlations of plasma total and serine protease activities 
with variables were calculated. in an in-vivo study, LDLR−/− mice were divided into normal chow 
diet, high-fat diet (HFD), and HFD with selective serine protease inhibition groups to examine the 
differences of obesity, blood glucose level, insulin resistance and serine protease activity among groups. 
Compared with controls, diabetic patients had significantly increased plasma total protease, serine 
protease activities, and also elevated inflammatory cytokines. Plasma serine protease activity was 
positively correlated with body mass index, hemoglobin A1c, homeostasis model assessment-insulin 
resistance index (HOMA-IR), tumor necrosis factor-α, and negatively with adiponectin concentration. 
In the animal study, administration of HFD progressively increased body weight, fasting glucose level, 
HOMA-IR, and upregulated serine protease activity. Furthermore, in-vivo serine protease inhibition 
significantly suppressed systemic inflammation, reduced fasting glucose level, and improved insulin 
resistance, and these effects probably mediated by modulating insulin receptor and cytokine expression 
in visceral adipose tissue. Our findings support the serine protease may play an important role in type 
2 diabetes and suggest a rationale for a therapeutic strategy targeting serine protease for clinical 
prevention of type 2 diabetes.
Metabolic syndrome is a global public health issue of increasing magnitude. Obesity, insulin resistance, proin-
flammatory and prothrombotic states, atherogenic dyslipidemia, and higher blood pressure are risk factors for 
metabolic syndrome1. Among these factors, obesity-induced insulin resistance is a major contributor to the 
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worldwide prevalence of type 2 diabetes. Although previous reports have suggested that obesity is correlated 
closely with insulin resistance1, the molecular mechanism involved in the development of obesity and related 
complications remains largely unclear. A large body of evidence suggests that obesity is associated with chronic 
adipose tissue inflammation, which may result in enhanced proinflammatory cytokine levels2. Obesity has been 
associated not only with larger adipocytes but also with increasing numbers of infiltrating macrophages in adi-
pose tissue3,4. These macrophages are currently suggested as a significant cause of obesity-associated chronic 
low-grade inflammation via the secretion of a wide variety of inflammatory molecules5.
Elevation of plasma protease activity was shown to be associated with diet-induced obesity and insu-
lin resistance or chronic inflammation3–9. Badeanlou et al. reported that diet-induced insulin resistance 
required protease-activated receptor 2 signaling activation3. Talukdar et al. demonstrated that the activation of 
neutrophil-derived elastase (a serine protease) is involved in high-fat diet (HFD)-induced insulin resistance, 
which suggests that proteases play a crucial role in obesity-induced insulin resistance and type 2 diabetes4. Obesity 
has also been found to increase neutrophil-derived elastase activity and decrease the serum level of α1-antitrypsin 
(an endogenous serine protease inhibitor) in mice and humans5. α1-Antitrypsin is associated with type 2 dia-
betes, as 50% of diabetic patients have low circulating α1-antitrypsin levels6,7. Furthermore, α1-antitrypsin has 
been shown to prevent type 1 diabetes development, prolong islet allograft survival, and inhibit pancreatic β-cell 
apoptosis in vivo8. Chronic inflammation-induced proteolytic matrix metalloproteinases cleave the extracellular 
domains of insulin receptors, induce soluble insulin receptor-α in human plasma, and promote insulin resist-
ance9. Interestingly, the recent evidence showed that the soluble insulin-receptor ectodomain is elevated in the 
plasma of patients with diabetes10, and the serine protease granzyme B is an inflammatory marker related to insu-
lin receptor cleavage in human obesity and type 2 diabetes mellitus11. Accordingly, protease activity inhibition 
is thus a potential therapeutic target to improve impaired metabolism and insulin resistance in obese subjects.
The present study is aimed to test the hypothesis that serine protease plays a pivotal role in patients with 
type 2 diabetes. Low-density lipoprotein (LDL) receptor knockout (LDLR−/−) mice with HFD has been used as 
the diet-induced obesity and diabetes mouse model12. We investigated the postulated mechanisms that elevated 
plasma serine protease activities which may cause excessive proteolytic cleavage of insulin receptor-α followed 
by insulin resistance and related abnormal metabolic parameters in this mouse model. Furthermore, we explored 
the possible therapeutic effects of 4-(2-aminoethyl) benzenesulfonyl fluoride hydrochloride (AEBSF), a selective 
serine protease inhibitor.
Results
Baseline characteristics of human study. Table 1 summarizes the demographic and clinical charac-
teristics of the human study subjects. As expected, diabetic patients had significantly higher fasting glucose and 
hemoglobin A1c (HbA1c) levels, waist circumference, and body mass index (BMI) than did patients without dia-
betes. Compared with the non-diabetic group, patients with diabetes had elevated levels of inflammatory markers, 
including IL-6 and high-sensitivity C-reactive protein (hs-CRP), and decreased adiponectin levels. There was no 
difference in lipid profiles, including total cholesterol, LDL cholesterol (LDL-c), and triglycerides between groups, 
except that patients with diabetes had lower high-density lipoprotein cholesterol (HDL-c) levels.
increased total and serine protease activities in patients with diabetes. As shown in Fig. 1A, total 
plasma protease activity was significantly higher in diabetic patients than in those without diabetes (non-DM vs. 
DM, 1848 vs. 1999 RFU; p = 0.010). Total plasma protease activity was positively correlated with BMI (r = 0.338, 
p < 0.001), HBA1c (r = 0.237, p = 0.036), and fasting glucose level (r = 0.271, p = 0.014; Fig. 1B–D). However, 
there was no significant difference in MMP-9 and MMP-13 levels between groups (Supplementary Fig. 1A).
Additionally, plasma serine protease activity levels were significantly enhanced in patients with diabetes than in 
those without diabetes (non-DM vs. DM, 0.2092 vs. 0.2457 OD, p = 0.028; Fig. 1E). Plasma serine protease activity 
was also positively correlated with BMI (r = 0.14, p = 0.0001), HBA1c level (r = 0.255, p = 0.019; Fig. 1F–H), home-
ostasis model assessment of insulin resistance (HOMA-IR) (r = 0.256, p = 0.017), insulin level (r = 0.213, p = 0.048), 
and negatively with adiponectin concentration (r = −0.264, p = 0.014). Additionally, serine protease activity was 
correlated positively with tumor necrosis factor-α (TNF-α) (r = 0.274, p = 0.011), but not with hs-CRP (r = 0.209, 
p = 0.056), and IL-6 levels (r = 0.017, p = 0.874; Supplementary Fig. 1B–D). However, total protease activity showed 
no positive correlation with any of the above parameters (Supplementary Fig. 2A–F). Together, these findings indi-
cate that serine protease activity was associated more significantly than total protease activity with type 2 diabetes 
mellitus.
LDLR−/− mice fed an HFD developed insulin resistance and type 2 diabetes. Compared with 
mice fed the normal chow diet, HFD-fed mice showed significant body weight increase at 4 weeks (25.5 ± 1.0 
vs. 27.6 ± 1.7 g, p < 0.05; Fig. 2A) and higher fasting glucose level at 6 weeks (130.6 ± 15.0 vs. 161.8 ± 28.1 mg/
dl, p < 0.05; Fig. 2B). Besides, HOMA-IR was significantly higher in HFD-fed mice after 3 weeks (4.4 ± 0.3 vs. 
1.8 ± 0.2, p < 0.05; Fig. 2C). Consistent with these findings, HFD-fed mice had higher glucose (542.6 ± 99.3 vs. 
427.3 ± 27.9 mg/dl, p < 0.05; Fig. 2D) and serum insulin (1.4 ± 0.3 vs. 0.9 ± 0.2 ng/ml, p < 0.05; Fig. 2E) levels 
than did standard chow-fed mice at 30 min after the IPGTT glucose challenge. Compared with chow-fed mice, 
HFD-fed mice had significantly higher plasma total protease (3703.6 ± 723.0 vs. 4994.4 ± 711.2 RFU, p < 0.05; 
Fig. 2F) and serine protease (0.4 ± 0.1 vs. 1.1 ± 0.2 OD, p < 0.05; Fig. 2G) activity levels from week 2. Circulating 
adiponectin levels were decreased by 31%, and leptin markedly increased in HFD-fed mice compared with 
chow-fed mice at week 10 (Table 2). These data suggest that the HFD induced upregulation of plasma total pro-
tease and serine protease activities followed by insulin resistance, weight gain, blood glucose elevation and finally 
alteration of adipokines in LDLR−/− mice.
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Effects of serine protease inhibitor on fasting glucose level and insulin resistance in LDLR−/− 
mice fed an HFD. Compared with the chow diet, the HFD significantly increased fasting glucose, total cho-
lesterol, HDL-c, LDL-c, and triglyceride levels, and decreased the total bilirubin level, in LDLR−/− mice; AEBSF 
attenuated these effects (all p < 0.05; Table 2). AEBSF treatment significantly increased total bilirubin levels com-
pared to HFD or chow control (Table 2). AEBSF treatment also elevated alkaline phosphatase levels compared to 
HFD group (Table 2). AEBSF treatment significantly lessened the TNF-α level and upregulated the circulating 
adiponectin concentration (both p < 0.05; Table 2). As expected, AEBSF inhibited plasma serine protease activity 
at 2 weeks (1.1 ± 0.2 vs. 0.5 ± 0.07 OD, p < 0.05; Fig. 2D), but did not suppress total protease activity (Fig. 2E).
AEBSF treatment resulted in significant reductions in HFD-induced body weight gain (Fig. 2A), fasting 
blood glucose level (Fig. 2B), and HOMA-IR (Fig. 2C). At 10 weeks, glucose and insulin levels were significantly 
improved in mice treated with AEBSF compared with vehicle-treated mice (30 min after i.p. glucose injection: 
glucose, 423.0 ± 81.4 vs. 542.6 ± 99.3 mg/dl; insulin, 0.4 ± 0.1 vs. 1.4 ± 0.3 ng/ml; both p < 0.05; Fig. 2F–G). These 
results suggest that AEBSF attenuated HFD-induced insulin resistance in LDLR−/− mice.
Serine protease inhibitor improved the decreased insulin signaling in visceral fat tissue. 
HFD-fed mice showed a reduced ratio of protein levels of insulin receptors α and β in visceral adipose (VAD) 
tissue, but there was no significant effect in muscle or liver tissue (Fig. 3A–E). AEBSF treatment significantly 
reversed this effect in VAD tissue compared with HFD-fed mice (0.8 ± 0.2 vs. 0.6 ± 0.2, p < 0.05; Fig. 3A–E). 
Protein levels indicated that phosphorylation of pyruvate dehydrogenase kinase isozyme 1 (PDK1), Akt, and 
glycogen synthase kinase 3β (GSK3β) was downregulated in VAD tissue, but not in muscle or liver tissue. Unlike 
Akt that has to be phosphorylated before activation, GSK3β is constitutively active in resting cells, requiring 
phosphorylation by kinases such as AKT to inactivate it. AEBSF treatment resulted in a modest recovery of 
downregulation of PDK1, Akt, and upregulation of GSK3β in VAD tissue (all p < 0.05). Thus, insulin signaling 
was downregulated in VAD tissue in LDLR−/− mice fed a HFD, and AEBSF induced partial recovery from this 
suppression effect.
No diabetes 
(n = 30)
Type 2 diabetes 
(n = 57) p
Age (years) 47.8 ± 12.9 53.3 ± 11.5 0.05
Male 16 (53.3%) 37 (64.9%) 0.293
Hyperlipidemia 7 (23.3%) 27 (47.4%) 0.029
Hypertension 5 (16.7%) 21(36.8%) 0.051
Coronary artery disease 2 (6.7%) 7 (12.3%) 0.713
Current smoker 0 (0%) 14 (24.6%) 0.002
Waist circumference (cm) 82.9 ± 9.7 91.0 ± 10.4 0.001
BMI (kg/m2) 23.8 ± 3.5 26.7 ± 3.5 0.001
SBP (mmHg) 114.4 ± 12.6 127.2 ± 16.7 <0.001
DBP (mmHg) 74.5 ± 7.0 82.1 ± 11.2 0.001
PR (/min) 69.6 ± 11.1 76.1 ± 11.8 0.015
Creatinine (mg/dl) 0.8 ± 0.2 0.8 ± 0.2 0.198
ALT (u/l) 26.0 ± 16.8 38.1 ± 25.3 0.06
Glucose (mg/dl) 89.7 ± 10.5 126.2 ± 31.8 <0.001
HbA1c (%) 5.6 ± 0.4 6.7 ± 0.7 <0.001
Total cholesterol (mg/dl) 186.9 ± 37.1 181.8 ± 41.2 0.64
Triglyceride (mg/dl) 113.9 ± 100.3 132.0 ± 63.9 0.38
LDL-c (mg/dl) 105.4 ± 30.9 112.0 ± 35.1 0.54
HDL-c (mg/dl) 61.1 ± 17.3 43.8 ± 14.6 0.001
Aspirin use 2 (6.7%) 4 (7.0%) 1.000
Statin use 7 (8%) 23 (26.4%) 0.112
ACEI/ARB use 4 (13.3%) 20 (35.1%) 0.043
CCB use 2 (6.7%) 11 (12.6%) 0.204
Oral hypoglycemic agent use 0 (0.0%) 46 (80.7%) <0.001
TNF-α (pg/ml) 4.1 ± 1.9 4.5 ± 2.9 0.5
IL-6 (pg/ml) 1.6 ± 0.7 2.6 ± 1.6 0.003
hs-CRP (μg/ml) 1.2 ± 1.5 2.4 ± 2.4 0.016
Adiponectin (μg/ml) 8.2 ± 5.7 5.3 ± 3.9 0.007
Resistin (μg/ml) 10.1 ± 6.0 11.0 ± 6.1 0.5
Table 1. Basic characteristics of study subjects. Values are means ± standard deviations or n (%). SBP: 
systolic blood pressure; DBP: diastolic blood pressure; PR: pulse rate; ALT: alanine aminotransferase; HbA1c: 
hemoglobin A1c; ACEI/ARB: angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; CCB: 
calcium channel blocker; TNF-α: tumor necrosis factor-alpha; IL-6: interleukin 6; hs-CRP: high-sensitivity 
C-reactive protein.
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The HFD promoted serine protease activation; IL-6, IL-10, and TNF-α proteins expression; and upregulation 
of the macrophage-related markers CD11b and F4/80 in VAD tissue (Fig. 3F–H). AEBSF significantly down-
regulated these activities, except for IL-10 expression. Together, the HFD induced serine protease activity and 
triggered inflammatory cytokines secretion, and AEBSF attenuated these effects.
Discussion
The study results suggest that circulating serine protease activity is significantly elevated and associated with 
HBA1c, HOMA-IR, TNF-α, and adiponectin levels in patients with type 2 diabetes. Animal experiments in 
LDLR−/− mice confirmed these findings that administration of HFD produced progressive hyperglycemia and 
insulin resistance associated with upregulation of serine protease activity in plasma and VAD tissue. By showing 
a reduced ratio of protein levels of insulin receptors-α and β in VAD, we suggest that HFD will produce exces-
sive proteolytic cleavage of the extracellular domain of insulin receptors in VAD (not in liver nor muscle tissue), 
thereby further advancing the knowledge in this field. It is worth noting that the treatment of the selective serine 
protease inhibitor AEBSF significantly attenuated the diabetogenic effects of HFD through the suppression of 
systemic inflammation, enhancement of adiponectin concentration, and improvement of insulin sensitivity in 
this animal model.
The pathogenesis of obesity-induced diabetes is multifactorial and complex. α1-Antitrypsin is known to play 
a pivotal role in blocking the early stage of proinflammatory cytokine production in mice with HFD-induced 
obesity5. Serine protease activation is likely involved in the inflammation of HFD-induced obesity. These studies 
clarified serine protease expression in subjects with diabetes mellitus and its action in diet-induced obesity. We 
showed that patients with diabetes have greater total and serine protease activities, in association with higher 
BMI and systemic inflammation. Moreover, plasma serine protease activity was positively correlated with BMI, 
HBA1c, fasting glucose levels, HOMA-IR, TNF-α, and also negatively with adiponectin concentration. However, 
the total protease activity showed no significant correlation with any of the above parameters. These findings 
provide novel evidence that serine protease activity was associated more significantly than total protease activity 
in patients with type 2 diabetes mellitus.
Figure 1. Total and serine protease activity levels were increased in patients with type 2 diabetes mellitus. 
Total protease activity in plasma (A; diabetes, n = 57; no diabetes, n = 30) was correlated incrementally with 
hemoglobin A1c (HBA1c) level (B), fasting glucose level (C), and BMI (D). Serine protease activity in plasma 
(E) was correlated incrementally with HBA1c level (F), fasting glucose level (G), and BMI (H).
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Obesity has been established as an important factor in the etiology of insulin resistance and type 2 diabetes13. 
Tissue factor protease-activated receptor 2 signaling was shown to promote diet-induced obesity and insulin 
resistance3. In the present study, glucose level and HOMA-IR were significantly elevated in HFD-fed than in 
chow-fed LDLR−/− mice. These results suggest that the glucose challenge mediated insulin secretion in the cir-
culation, but the increased insulin had only a minor effect on the promotion of glucose uptake by peripheral 
tissue. These phenomena were confirmed by the IPGTT, in which the glucose challenge increased blood glucose 
and insulin levels and reduced glucose clearance in the circulation. Besides, HFD-induced increases in systemic 
inflammation and serine protease activity were also observed in LDLR−/− mice. Inhibition of serine protease by 
AEBSF diminished the effects of the HFD on HOMA-IR, fasting glucose level, and blood glucose and insulin 
levels in the IPGTT, confirming that inhibition of serine protease reduced HFD-induced insulin resistance in 
LDLR−/− mice. Our data are in line with previous reports that reduced α1-antitrypsin levels were correlated neg-
atively with BMI in obese humans5, and HFD-induced insulin resistance is attenuated by adipose tissue-derived 
serpins9.
Proteases derived from diverse sources are important mediators of HFD-induced obesity and diabetes. An 
HFD appears to cause protease and antiprotease imbalances in circulation5. Our study showed that inhibition 
of serine protease recovered HFD-related impaired insulin signaling in VAD tissue in LDLR−/− mice, which 
suggests specific suppression of serine protease activity may prevent the destruction of the extracellular domain 
Figure 2. 4-(2-Aminoethyl) benzenesulfonyl fluoride hydrochloride (AEBSF) attenuated high-fat diet (HFD)-
induced obesity and insulin resistance in male LDLR−/− mice. (A) HFD-induced weight gain (n = 6–9/group). 
(B) Plasma concentrations of fasting glucose (B; n = 6−12/group) and Homeostatic Model Assessment of 
Insulin Resistance (HOMA-IR; C; n = 6−9/group) in mice receiving HFD and HFD + AEBSF treatments. 
Plasma concentrations of glucose (D) and insulin (E) in an intraperitoneal glucose tolerance test for mice 
receiving the chow, HFD, and HFD + AEBSF treatments (n = 6/group). Total (F) and serine (G) protease 
activities in mice receiving the chow, HFD, and HFD + AEBSF treatments (n = 6/group) *P < 0.05, chow vs. 
HFD; ♯p < 0.05, HFD vs. HFD + AEBSF. Values are means ± standard deviations.
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of insulin receptor-α, and protects insulin receptors. These findings support previous reports about the solu-
ble insulin-receptor ectodomain elevated in human obesity and type 2 diabetes mellitus10,11. Additionally, we 
extended previous findings showing that HFD produced excessive proteolytic cleavage of extracellular domain of 
insulin receptors in VAD not in liver nor muscle tissues. The excessive cleavage resulted in decreased detection 
of insulin receptor-α and impaired insulin signaling cascade in VAD in this study. Little is known about insulin 
receptor-α in animal study. Recently, it was reported that hyperinsulinemia would promote proteolytic cleavage 
of insulin receptor-α in rat hepatocyte culture14. They found increased proteolytic cleavage of insulin receptor in 
culture medium with higher insulin concentration14. HFD induced more complex changes in mice than simply 
hyperinsulinemic condition. Elevated serine protease activity in VAD, not liver, seems to play an important role 
in HFD-induced obesity in our study.
A variety of immune cells have been shown to participate in the complex intracellular communication net-
work that organizes the chronic inflammatory response to obesity4. TNF-α and IL-6 are considered to be con-
tributors to insulin resistance and diabetes mellitus development15,16. In this study, AEBSF attenuated increases 
in TNF-α and IL-6 levels in HFD-fed mice. Serine protease could be considered to be an active participant in 
obesity-induced inflammation and insulin resistance. These results are consistent with those of previous studies 
showing that polymorphonuclear neutrophil-derived serine proteases hydrolyze peptide bonds of TNF-α precur-
sors and produce mature cytokine molecules17. Targeting inflammatory pathways could possibly be a component 
of the therapeutic strategies to prevent and control insulin resistance and diabetes.
Furthermore, adiponectin and leptin, an adipokine produced exclusively by adipocytes, are known to have 
critical effects on body weight regulation18. In this study, circulating adiponectin levels were significantly lower 
in participants with diabetes and HFD-fed LDLR−/− mice compared with controls. Selective inhibition of ser-
ine protease attenuated HFD-suppressed adiponectin levels. These findings are in agreement with the previous 
demonstration of improved insulin sensitivity in vaspin-suppressed obese mice fed high-fat, high-sucrose chow, 
as reflected by leptin and TNF-α downregulation and adiponectin upregulation19. Lower circulating adiponectin 
levels have been observed in patients with obesity and type 2 diabetes compared with lean subjects, and have 
been associated with insulin sensitivity, lipid and glucose metabolism, and inflammation20,21. AEBSF attenuated 
HFD-induced circulating IL-6 accumulation and recovered HFD-suppressed circulating adiponectin production. 
It also attenuated HFD-increased IL-6, CD11b, F4/80, and TNF-α expression and serine protease activity in VAD 
tissue. These data suggest that serine protease activity inhibition reduces adipose tissue inflammation, improving 
insulin sensitivity, in HFD-fed LDLR−/− mice. Endogenous serine protease inhibitor may exert insulin-sensitizing 
effects on white adipose tissue in various states of obesity19.
Previous studies have shown that administration of an endogenous serine protease inhibitor is correlated 
negatively with BMI and overcomes insulin resistance in obese mice5,19. However, details of the underlying 
mechanisms remained largely unknown. To clarify whether and how a serine protease inhibitor could modify 
insulin sensitivity, three kinases in the insulin signaling cascade (PDK1, Akt, and GSK3β) were examined in 
liver, muscle, and VAD tissues in HFD-fed LDLR−/− mice. Glucose and insulin levels were higher in HFD-fed 
mice after the IPGTT glucose challenge, and were reduced by AEBSF. In addition, AEBSF recovered the baseline 
phosphorylation status of all three kinases in VAD tissue, but not in liver or muscle tissue, in HFD-fed mice, 
indicating the selective tissue-specific improvement of insulin sensitivity. AEBSF mediated the recovery of insulin 
receptor-α/β, phosphorylation of PDK1, Akt, and GSK3β protein levels, contributing, at least partially, to resist-
ance to HFD-induced insulin signaling loss in LDLR−/− mice. Our findings provide initial evidence suggesting 
that insulin receptors in VAD tissue are the main targets of serine protease inhibition, which reduces systemic 
inflammation and insulin resistance in experimental diabetes. VAD is known to play a critical pathophysiological 
Chow
(n = 7)
HFD
(n = 9)
HFD + AEBSF
(n = 9)
Glucose (mg/dl) 105.4 ± 15.5 205.3 ± 24.2* 155.5 ± 18.6#&
Cholesterol (mg/dl) 255.7 ± 42.5 974.7 ± 95.2* 519 ± 65.4#&
HDL-c (mg/dl) 60.1 ± 11.1 285.8 ± 15.3* 239.5 ± 40.8#&
LDL-c (mg/dl) 91 ± 17.9 537.3 ± 43.3* 429 ± 90.4#&
Triglycerides (mg/dl) 109.3 ± 8.5 338.6 ± 48.2* 230 ± 16.6#&
TNF-α (pg/ml) 1.4 ± 0.22 3.2 ± 0.4* 2.4 ± 0.2#&
IL-6 (pg/ml) 5.8 ± 2.0 19.4 ± 6.2* 14.8 ± 5.7#&
Leptin (μg/ml) 0.94 ± 0.27 6.60 ± 2.41* 2.71 ± 0.68#&
Adiponectin (μg/ml) 38.12 ± 8.3 26.19 ± 4.82* 36.3 ± 5.27#
Resistin (μg/ml) 14.59 ± 4.4 25.56 ± 7.57* 22.43 ± 8.16&
BUN (mg/dl) 25 ± 1 34 ± 6.7* 30.2 ± 3.5&
Creatinine (mg/dl) 0.12 ± 0.01 0.2 ± 0.08* 0.22 ± 0.06&
Total bilirubin (mg/dl) 0.26 ± 0.07 0.12 ± 0.1* 0.36 ± 0.1#&
ALP (u/l) 68.2 ± 15 62.9 ± 15 83 ± 19.3#
Table 2. Metabolic parameters at 10 weeks of dietary control in LDLR−/− mice. Values are means ± standard 
deviations. *p < 0.05, chow vs. HFD; #p < 0.05, HFD vs. HFD + AEBSF; &p < 0.05, Chow vs. HFD + AEBSF. 
HFD: high-fat diet; AEBSF: 4-(2-aminoethyl) benzenesulfonyl fluoride hydrochloride; TNF-α: tumor necrosis 
factor-alpha; IL-6: interleukin 6; BUN: blood urea nitrogen; ALP: alkaline phosphatase.
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role in clinical metabolic syndrome and type 2 diabetes. Interestingly, a recent study reported that the amount of 
biologically insulin receptor active is regulated by the cleavage of its ectodomain, by the β-site amyloid precursor 
protein cleaving enzyme 1 (BACE1), in a glucose concentration-dependent manner22. They demonstrated that 
BACE1 (an aspartyl protease, not serine protease) regulated the cleavage of insulin receptor and insulin signaling 
mainly in db/db mouse livers22. In contrast, we confirmed upregulation of serine protease in VAD (not liver or 
muscle) play some role in HFD-induced insulin resistance in LDLR−/− mice in concordance with the previous 
studies5,19. We speculated that different pathophysiological mechanisms may exist in different diabetic models 
(HFD-induced diabetes vs. db/db mice). Further studies are warranted to validate this speculation.
This study has several limitations. First, many proteases are active in blood23. Serine protease was shown to 
exert a crucial role in HFD-induced diabetes development, but interaction by other proteases in this study cannot 
be ruled out. Second, we investigated total serine protease activities in blood and VAD but not specific protease 
such as vaspin. The identity of the serine protease involved in obesity-associated diabetes development remains 
unclear; future studies should use activity-based probes to identify potential candidates. Third, the influence of 
serine hydrolase, which has a similar active site as serine protease23, was not investigated in the present study; 
its function may also be blocked by AEBSF. That is, the attenuation of serine hydrolase may have contributed to 
the improvement in lipid metabolism after AEBSF treatment in LDLR−/− mice24. Also, it would be important to 
understand if there is a combined action to generate the improvement in lipid metabolism after AEBSF treatment. 
In addition, we explored the insulin signaling pathway by investigating tissue insulin receptor-α and three kinases 
in the signaling cascade, PDK1, Akt, and GSK3β. The other important parameters (insulin receptor substrate 1 
and glucose transporter type 4 in signaling cascade and plasma soluble insulin receptor-α) may provide further 
information about the roles of insulin receptor-α/β in insulin receptor function and signalling. The study is still 
preliminary and the nature of human and mouse plasma and VAD proteases need to be established. Furthermore, 
the potential side effect of AEBSF is unclear. In this study, we found significantly elevated levels of total bilirubin 
in AEBSF treatment group compared to chow diet and HFD group.
Figure 3. 4-(2-Aminoethyl) benzenesulfonyl fluoride hydrochloride (AEBSF) recovered high-fat diet 
(HFD)-impaired insulin signaling and inflammation in visceral adipose (VAD) tissue of LDLR−/− mice. (A) 
The peripheral-tissue insulin signaling pathway [insulin receptor, pyruvate dehydrogenase kinase isozyme 1 
(PDK1), Akt, glycogen synthase kinase 3β (GSK3β)] was analyzed by western immunoblots. (B) Quantification 
of insulin receptor-α and -β expression, measured by imageQuant. Amounts of phosphorylated and total PDK1 
(C), Akt (D), and GSK3β (E). (F) VAD tissue inflammatory cytokines and macrophage markers [interleukin 
(IL)-6, IL-10, CD11b, F4/80] were analyzed by western immunoblots, with protein levels quantified by 
imageQuant. (G) Tumor necrosis factor-α (TNF-α) expression in VAD tissue was analyzed by ELISA. (H) 
Serine protease activity in VAD tissue of mice receiving the chow, HFD, and HFD + AEBSF treatments (n = 6/
group). *P < 0.05, chow vs. HFD; ♯p < 0.05, HFD vs. HFD + AEBSF. Values are means ± standard deviations. 
Full-length blots were presented in Supplementary Figs. 3 and 4.
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In conclusion, serine protease activity is increased in clinical and experimental diabetes, which may be critical 
for type 2 diabetes development. As depicted in Fig. 4, the specific serine protease inhibitor AEBSF attenuated 
systemic inflammation, obesity, and insulin resistance in diabetic mice, probably by modulating insulin receptor 
and cytokine expression in VAD tissue. Our findings support the potential role of serine proteinase as the thera-
peutic target for clinical prevention of type 2 diabetes. Further clinical studies are required to verify this concept.
Methods
Human study: population, design, and measurements. We conducted a single-center, cross-sec-
tional study with 87 subjects from Taipei Veterans General Hospital, Taipei, Taiwan. Study subjects were divided 
into two groups: type 2 diabetes mellitus and no diabetes. Diabetes mellitus was diagnosed by anti-hyperglycemic 
agent use or American Diabetes Association criteria25. All subjects apart from those reporting the prior diagnosis 
of diabetes underwent a standard 75-g oral glucose tolerance test, which included the measurement of fasting glu-
cose. Subjects were excluded using the following criteria: (1) age < 18 years or >80 years, (2) receipt of insulin or 
insulin analog, (3) renal and/or liver function impairment, and (4) HbA1c > 8.0% (64 mmol/mol). The study pro-
tocol was approved by Institutional Review Board of Taipei Veterans General Hospital, Taipei, Taiwan (VGHIRB 
no. 201001004IC). All participants provided written informed consent before entering the study. In addition, all 
methods were performed in accordance with relevant guidelines and regulation.
Blood samples were collected after a ≥12-h fast and examined using biochemical tests to determine creatinine, 
alanine aminotransferase (ALT), glucose, HbA1c, and lipid profiles. To examine the role of circulating proteases 
in type 2 diabetes, plasma total and serine protease activities were determined. Protease-related markers, such 
as MMP-9 and MMP-13, were analyzed by Quantikine human ELISA kits (R&D Systems, Minneapolis, MN).
HFD-induced diabetes mouse model. We used a murine model to clarify the role of serine protease 
in obesity and dysglycemia development. All experimental procedures and protocols involving animals were 
approved by the institutional animal care committee of National Yang-Ming University, Taipei, Taiwan [IACUC 
approval no. IACUC-1030306 (YM)], and were carried out in accordance with the Guidelines for the Care and 
Use of Laboratory Animals. Thirty 8-week-old male LDLR−/− mice (C57BL/6 J background) were obtained from 
The Jackson Laboratory (Sacramento, CA, USA), and housed under standard 12/12-h light/dark conditions. They 
were divided randomly into a chow diet control group, a HFD group (positive control), and a HFD + AEBSF 
group. The chow diet (Picolab Rodent Diet 20; 4 kcal/g, 2% cholesterol, 5.7% fat) and HFD (Teklad diet TD 88137; 
4.5 kcal/g, 0.2% cholesterol, 21.2% fat; Harlan Tackle Co.) were administered for 10 weeks. An HFD is known to 
trigger the development of obesity and type 2 diabetes mellitus in LDLR−/− mice12. Mice in the HFD + AEBSF 
group received AEBSF (5 mg/kg/day; once a day, 5 days/week, intraperitoneal injection), and those in the HFD 
control group received PBS (100 μl/day, 5 days/week, intraperitoneal injection), for 10 weeks. AEBSF (Sigma, 
St. Louis, MO, USA), which inhibits serine protease activity by irreversible covalent bonding to the enzyme, 
was administered to clarify whether the pharmacological inhibition of serine protease could reverse obesity and 
improve insulin sensitivity in HFD-fed mice.
Figure 4. Schematic overview of the contributions of serine protease to insulin resistance and obesity in high-
fat diet (HFD)-fed LDLR−/− mice. These mice showed increased plasma total and serine protease activities, 
weight gain, and attenuated accumulation of insulin receptor-α in visceral fat tissue. Serine protease destroyed 
insulin receptor-α, contributing to insulin resistance. 4-(2-Aminoethyl) benzenesulfonyl fluoride hydrochloride 
(AEBSF) reversed insulin resistance and weight gain. However, the detailed mechanism of the weight gain 
reversal, adiponectin revision, and cholesterol and blood glucose lowering effects remains unclear.
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Measurements. Food intake, body weight, and blood glucose and insulin levels were recorded weekly. Mice 
were fasted overnight, and blood samples were collected from the facial vein. The intraperitoneal glucose toler-
ance test (IPGTT) was administered at 9 weeks, as described previously26. Briefly, after overnight fasting, each 
mouse was given an intraperitoneal injection of 1 g glucose kg−1 body weight using 50% glucose in 0.9% NaCl. 
Blood glucose concentrations were measured from a nicked tail vein at 0 (baseline), 30, 60, and 120 min after 
glucose injection using a blood glucose meter. Blood collected at these time points was isolated for the detection 
of circulating insulin levels.
After 10 weeks of treatment, mice were fasted overnight and sacrificed by exsanguination under adequate 
anesthesia [ketamine-HCl (100 mg/kg) and xylazine (20 mg/kg), intraperitoneal injection). The thoracic cavity 
was opened, a blood sample was collected, and the liver, VAD, and muscle tissues were isolated, frozen quickly 
in liquid nitrogen, and stored at −80 °C for later analysis. To explore the molecular mechanism involved in the 
activation of serine protease-regulated metabolic functions, these tissues were used to quantify insulin signaling. 
Mouse serum was used to quantify lipid, adipokine, and cytokine levels.
Fasting serum insulin, glucose, total cholesterol, triglyceride, LDL-c, HDL-c, creatinine, blood urea nitro-
gen (BUN), aspartate transaminase, and ALT levels were measured. The HOMA-IR was used to calculate insu-
lin resistance. Glucose was assessed with a glucose meter (Optium Xceed™ diabetes monitoring system; Vic., 
Australia). Serum fasting insulin, leptin, adiponectin (an insulin-sensitizing adipokine), resistin, TNF-α, and 
hs-CRP levels were determined by ELISA (R&D Systems, Minneapolis, MN).
Reagents. Mouse TNF-α and fluorescent protease assay kits were obtained from Life Technologies (Grand 
Island, NY, USA). Antibodies against mouse insulin receptor-α (ab-78424), mouse insulin receptor-β (ab-80527), 
cluster of differentiation molecule 11b (CD11b) (ab-75476), and F4/80 (ab-6640) were obtained from Abcam Inc. 
(Cambridge, UK). Antibodies against mouse PDK1 (#3062), phospo-PDK1 (#3438), Akt (#9272), phospho-Akt 
(#9271), GSK3β (#9315), and phospho-GSK3β (#9336) were obtained from Cell Signaling Technology (Danvers, 
MA, USA). Antibodies against mouse interleukin (IL)-6 (MAB-406) and IL-10 (AF-519) and all proteins were 
detected using horseradish peroxidase (HRP)-conjugated secondary antibodies (R&D Systems, Minneapolis, 
MN). Antibodies against mouse actin (sc-47778) and all proteins were detected using HRP-conjugated secondary 
antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Unless otherwise specified, all other chemicals and 
reagents were obtained from Sigma-Aldrich (St. Louis, MO, USA).
Glucose homeostasis. HOMA-IR was calculated as [fasting insulin (pmol/l) × fasting glucose 
(mmol/l)]/13527. The early secretory response of insulin to an oral glucose load (Δinsulin 30 − 0/Δglucose 
30 − 0) was calculated as [Δ insulin (30 min − 0 min)]/[Δ glucose (30 min − 0 min)]. The incremental (above the 
baseline value) areas under the curve for glucose and insulin were calculated using GraphPad 5.0.
Western blot analysis. Skeletal muscle, liver, and VAD tissue lysates were prepared by dissection and homog-
enized in buffer (25 mM HEPES, pH 7.4; 1% Nonidet P-40; 137 mM NaCl; 1 mM phenylmethylsulfonyl fluoride, 
10 μg/ml aprotinin, 1 μg/ml pepstatin, 5 μg/ml leupeptin) using a PRO 200 homogenizer (PROScientific, Oxford, CT, 
USA). The samples were centrifuged at 14,000 × g for 20 min at 4 °C, and supernatant protein concentrations were 
determined using a protein assay kit (Bio-Rad Laboratories, Inc., Hercules, CA, USA). Supernatants (50 μg) were 
resolved by SDS-PAGE and subjected to immunoblotting. Protein abundance was detected with antibodies against 
insulin receptor-α, insulin receptor-β, Akt1, phospho-Akt1, PDK1, phospho-PDK1, GSK3β, phospho-GSK3β, and 
β-actin. All proteins were detected with HRP-conjugated secondary antibodies using Chemiluminescence Reagent 
Plus (PerkinElmer Life Science, Boston, MA, USA), and quantified with a densitometer. All proteins were normal-
ized by β-actin, and specific protein phosphorylation was normalized by corresponding proteins.
casein protease activity assay. To assess the ability of plasma proteases to digest large globular proteins, 
we utilized the Enzchek protease assay kit (Enzchek BODIPY, casein derivative, catalogue no. E-6638; Molecular 
Probes, Carlsbad, CA, USA; cleaved by metallo-, serine, acid, and sulfhydryl proteases), which consists of casein 
internally quenched with Texas FITC fluorophores (Ex/Em: 505/513 nm) reconstituted in a digestion buffer. 
Plasma samples were tested simultaneously for overall protease activity. Protease activity levels were determined 
from fluorescent intensity after peptide cleavage following 18 h incubation at 37 °C (SpectraMax Gemini XS; 
Molecular Devices, Sunnyvale, CA, USA).
Serine protease activity assay. Human and mouse plasma serine protease activities were measured with 
suc-AAPF-pNA, a highly specific synthetic substrate for serine protease, according to methods described pre-
viously28. Mouse plasma and VAD tissue were thawed by addition to 1 ml tissue lysis buffer (2 mM Tris, pH 7.2; 
100 μM NaN3; 50 mM NaCl; 0.1% IGEPAL). Tissue was homogenized and centrifuged at 12,000 × g. Supernatants 
were then centrifuged in 0.22-μm SPIN-X filter tubes. For the protease activity assay, suc-AAPF-pNA was dis-
solved in dimethyl sulfoxide, and 1 μl 40-mM solution was added to a 100-μl volume of 10 μl mouse plasma or 
0.5 mg/ml lysate protein in tissue lysis buffer. Cleavage of suc-AAPF-pNA was followed by absorbance at 405 nm 
for 18 h incubation.
Statistical analysis. Continuous variables were expressed as means ± standard deviations, and categori-
cal variables were presented as frequencies and percentages. Differences between groups were analyzed using 
two-tailed Student’s t tests. Subgroup comparisons of categorical variables were performed using the chi-squared 
test and Fisher exact test. Correlations of plasma total and serine protease activities with variables in the study 
groups were calculated using Pearson’s product-moment correlation analysis. All tests were two sided and 
p < 0.05 was considered to be statistically significant. Statistical analyses were performed with SPSS software 
(version 17; SPSS Inc., Chicago, IL, USA).
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Data availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
Received: 18 January 2019; Accepted: 13 January 2020;
Published: xx xx xxxx
References
 1. Meigs, J. B. et al. Impact of insulin resistance on risk of type 2 diabetes and cardiovascular disease in people with metabolic 
syndrome. Diabetes Care 30, 1219–1225 (2007).
 2. Engin, A. The pathogenesis of obesity-associated adipose tissue inflammation. Adv. Exp. Med. Biol. 960, 221–245 (2017).
 3. Badeanlou, L., Furlan-Freguia, C., Yang, G., Ruf, W. & Samad, F. Tissue factor-protease-activated receptor 2 signaling promotes diet-
induced obesity and adipose inflammation. Nat. Med. 17, 1490–1497 (2011).
 4. Talukdar, S. et al. Neutrophils mediate insulin resistance in mice fed a high-fat diet through secreted elastase. Nat. Med. 18, 
1407–1412 (2012).
 5. Mansuy-Aubert, V. et al. Imbalance between neutrophil elastase and its inhibitor alpha1-antitrypsin in obesity alters insulin 
sensitivity, inflammation, and energy expenditure. Cell Metab. 17, 534–548 (2013).
 6. Piras, B. et al. Clinical phenotypes of Italian and Spanish patients with alpha1-antitrypsin deficiency. Eur. Respir. J. 42, 54–64 (2013).
 7. Sandström, C. S. et al. An association between Type 2 diabetes and alpha-antitrypsin deficiency. Diabet. Med. 25, 1370–1373 (2008).
 8. Fleixo-Lima, G. et al. Mechanistic evidence in support of alpha1-antitrypsin as a therapeutic approach for type 1 diabetes. J. Diabetes 
Sci. Technol. 8, 1193–1203 (2014).
 9. Mazor, R. & Schmid-Schönbein, G. W. Proteolytic receptor cleavage in the pathogenesis of blood rheology and co-morbidities in 
metabolic syndrome. Early forms of autodigestion. Biorheology 52, 337–52 (2015).
 10. Soluble Insulin Receptor Study Group. Soluble insulin receptor ectodomain is elevated in the plasma of patients with diabetes. 
Diabetes 56, 2028–2035 (2007).
 11. El-Mesallamy, H. O., Hamdy, N. M., Mostafa, D. M. & Amin, A. I. The serine protease granzyme B as an inflammatory marker, in 
relation to the insulin receptor cleavage in human obesity and type 2 diabetes mellitus. J. Interferon Cytokine Res. 34, 179–186 (2014).
 12. Schreyer, S. A., Vick, C., Lystig, T. C., Mystkowski, P. & LeBoeuf, R. C. LDL receptor but not apolipoprotein E deficiency increases 
diet-induced obesity and diabetes in mice. Am. J. Physiol. Endocrinol. Metab. 282, E207–214 (2002).
 13. Kahn, S. E., Hull, R. L. & Utzschneider, K. M. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 444, 
840–846 (2006).
 14. Hiriart, M. et al. Hyperinsulinemia is associated with increased soluble insulin receptors release from hepatocytes. Front Endocrinol. 
5, 95 (2014).
 15. Yamaguchi, K. et al. Blockade of interleukin 6 signalling ameliorates systemic insulin resistance through upregulation of glucose 
uptake in skeletal muscle and improves hepatic steatosis in high-fat diet fed mice. Liver International 35, 550–561 (2015).
 16. Stavropoulos-Kalinoglou, A. et al. Anti-tumour necrosis factor alpha therapy improves insulin sensitivity in normal-weight but not 
in obese patients with rheumatoid arthritis. Arthritis Res. Ther. 14, R160 (2012).
 17. Coeshott, C. et al. Converting enzyme-independent release of tumor necrosis factor alpha and IL-1beta from a stimulated human 
monocytic cell line in the presence of activated neutrophils or purified proteinase 3. Proc. Natl. Acad. Sci. USA 96, 6261–6266 (1999).
 18. Tschritter, O. et al. Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes 52, 
239–243 (2003).
 19. Hida, K. et al. Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc. 
Natl. Acad. Sci. 102, 10610–10615 (2005).
 20. Kawano, J. & Arora, R. The role of adiponectin in obesity, diabetes, and cardiovascular disease. J. Cardiometab. Syndr. 4, 44–49 
(2009).
 21. Hajer, G. R., van Haeften, T. W. & Visseren, F. L. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur. Heart J. 
29, 2959–2971 (2008).
 22. Meakin, P. J. et al. The beta secretase BACE1 regulates the expression of insulin receptor in the liver. Nat. Commun. 9, 1306 (2018).
 23. Long, J. Z. & Cravatt, B. F. The metabolic serine hydrolases and their functions in mammalian physiology and disease. Chemical Rev. 
111, 6022–6063 (2011).
 24. Gilham, D. et al. Inhibitors of hepatic microsomal triacylglycerol hydrolase decrease very low density lipoprotein secretion. FASEB 
J. 17, 1685–1687 (2003).
 25. American Diabetes Association. Standards of medical care in diabetes—2010. Diabetes Care 33, S11–S61 (2010).
 26. Huang, P. H. et al. Pioglitazone ameliorates endothelial dysfunction and restores ischemia-induced angiogenesis in diabetic mice. 
Biomed. Pharmacother. 62, 46–52 (2008).
 27. Hanley, A. J., Williams, K., Stern, M. P. & Haffner, S. M. Homeostasis model assessment of insulin resistance in relation to the 
incidence of cardiovascular disease: the San Antonio Heart Study. Diabetes Care 25, 1177–1184 (2002).
 28. Larcher, G. et al. Purification and characterization of a fibrinogenolytic serine proteinase from Aspergillus fumigatus culture filtrate. 
FEBS Lett. 308, 65–69 (1992).
Acknowledgements
This study was supported, in part, by research grants from the Ministry of Science and Technology of Taiwan 
(MOST 104-2314-B-075-047, MOST 106-2314-B-010-033-MY3, MOST 106-2314-B-075-078-MY3), the Novel 
Bioengineering and Technological Approaches to Solve Two Major Health Problems in Taiwan sponsored by the 
Taiwan Ministry of Science and Technology Academic Excellence Program (MOST 108-2633-B-009-001), the 
Ministry of Health and Welfare (MOHW106-TDU-B-211-113001) and from Taipei Veterans General Hospital 
(V105C-207, V106C-045, V108C-195). These funding agencies had no influence on the study design, data 
collection or analysis, decision to publish or preparation of the manuscript.
Author contributions
J.-S.C., G.W.S.-S., J.-W.C., S.C. and S.-J.L. conceived and designed the experiments. J.-S.C. and L.-Y.L. performed 
the experiments. J.-S.C., P.-H.H., L.-Y.L., G.W.S.-S. and J.-W.C. analyzed the data. J.-S.C., P.-H.H., L.-Y.L., J.-W.C. 
and S.-J.L. contributed reagents, materials, and analytical tools. J.-S.C., P.-H.H., L.-Y.L. and C.-S.K. wrote the 
paper. G.W.S.-S., J.-W.C. and S.-J.L. revised the article critically for important intellectual content. P.-H.H., J.-
W.C. and S.-J.L. are the guarantors of this work and, as such, had full access to all the data in the study and take 
responsibility for the integrity of the data and the accuracy of the data analysis.
1 1Scientific RepoRtS |         (2020) 10:1725  | https://doi.org/10.1038/s41598-020-58361-4
www.nature.com/scientificreportswww.nature.com/scientificreports/
Competing interests
The authors declare no competing interests.
Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41598-020-58361-4.
Correspondence and requests for materials should be addressed to P.-H.H., J.-W.C. or S.-J.L.
Reprints and permissions information is available at www.nature.com/reprints.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2020
